PRODUCT

SS-31 (10 mg Vial)

No short description available.

Quickstart Highlights

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome[3]. This educational protocol presents a once‑daily subcutaneous approach using concentrated reconstitution for practical insulin‑syringe measurements.

Reconstitute: Add 1.0 mL bacteriostatic water → 10 mg/mL concentration for single‑syringe convenience.
Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Reconstitution

Draw 1.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
Gently swirl/roll until fully dissolved (clear solution).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light; use within 4 weeks.
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

Protocol Overview

Goal:Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand[1][2].
Schedule:Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).
Dose Range:5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).
Reconstitution:1.0 mL per 10 mg vial (10 mg/mL) for convenient single‑syringe administration.
Storage:Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Dosage Protocols

Start:5 mg daily for Weeks 1–2 to assess individual tolerance.
Standard Target:10 mg daily by Week 3 (most common clinical trial dose).
Advanced Target:15–20 mg daily for Weeks 5+ (only for severe conditions under medical oversight).
Frequency:Once per day (subcutaneous injection); maintain consistent timing.
Cycle Length:8–12 weeks; limited data exists beyond 12 weeks.
Timing:Any consistent time; rotate injection sites to prevent tissue irritation.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for months when frozen.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 4 weeks for optimal stability. Avoid freeze–thaw:

Important Notes

Practical considerations for consistency, safety, and tolerability.

Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[14].
Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.
Mild injection‑site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials[4][6]; these typically resolve within hours.
Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns.
For doses requiring split injections (≥15 mg), space injections at least 2 inches apart on different body regions.

How It Works

SS‑31 (elamipretide) is a cell‑permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction[1]. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure[2][7]. By stabilizing cardiolipin‑protein interactions, SS‑31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues[8]. Preclinical research demonstrated that SS‑31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia‑reperfusion injury, neurodegeneration, chronic kidney disease, and age‑related muscle atrophy[9]. In human clinical trials, SS‑31 showed favorable safety and tolerability profiles with no dose‑limiting toxicities[4][5]. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six‑minute walk distance, leading to FDA accelerated approval in 2025[3][10].

Lifestyle Factors

Nutrition: Emphasize mitochondrial cofactors including B‑vitamins, CoQ10, magnesium, and alpha‑lipoic acid; maintain adequate protein intake to support muscle maintenance.
Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.
Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.
Stress Management: Chronic stress increases oxidative burden; incorporate stress‑reduction practices such as meditation, breathwork, or yoga.
Avoid Mitotoxins: Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.

Injection Technique

Site Preparation: Clean the vial stopper and injection site with alcohol swabs; allow to air‑dry completely (30–60 seconds) before proceeding[13].
Drawing the Dose: Use a new sterile insulin syringe for each injection; draw the prescribed volume from the refrigerated vial; remove any visible air bubbles by gently tapping the syringe.
Injection Angle: Pinch a fold of skin (approximately 1–2 inches); insert the needle at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean)[11][12].
Administration: Do not aspirate for subcutaneous injections[11]; inject slowly and steadily over 3–5 seconds; wait 5–10 seconds before withdrawing the needle to minimize leakage.
Site Rotation: Rotate systematically between injection sites (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent lipohypertrophy and local irritation[14].
Post‑Injection: Apply gentle pressure with a clean alcohol swab or cotton ball for a few seconds; do not massage the site vigorously. A small bandage may be applied if needed.
Disposal: Immediately place used syringes in a designated sharps container; never recap needles or dispose of them in regular trash.

Benefits and Side Effects

Benefits

Observations from preclinical models and human clinical trials.

SS-31 (10 mg Vial)

Resources

Categories

Company